SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ggamer who wrote (111)5/23/2007 2:08:28 PM
From: Keith FeralRead Replies (1) of 418
 
I don't recall the statement, but here is the size of the product markets for which Cofactor and other drugs are seeking to replace.

Leucovorin - $500 million. 80% of that number is generic.
Vinorelbine - $200 million.
Docetaxel - $2 billion.
Thiovir - $4.9 billion.
Anti Virals - I forget the numbers.

If you listen to the slide presentation of Adventrx's web site on the Investors page, you will be able to get up to speed with all of the existing drugs they are seeking to replace.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News